All year our Weekly Checkup calculated the biggest gainers and losers among publicly traded medical device companies, comparing Monday morning’s opening share prices with their value when the markets close each Friday afternoon. As 2009 draws to a close, we’re taking a look at the 20 firms that posted the biggest share price gains and losses during the year, from Jan. 5 through Dec. 16.
The 10 biggest gainers:
- Imaging3 Inc. (OTC:IMGG): 1,157% (open $0.07, close $0.88)
- Candela Corp. (NSDQ:CLZR): 415% (open $0.52, close $2.68)
- Quick-Med Technologies Inc. (OTC:QMDT): 408% (open $0.12, close $0.61)
- Ophthalmic Imaging Systems (OTC:OISI): 333% (open $0.15, close $0.65)
- Endologix Inc. (NSDQ:ELGX): 316% (open $1.16, close $4.83)
- Trimedyne Inc. (OTC:TMED): 285% (open $0.13, close $0.50)
- NeuroMetrix Inc. (NSDQ:NURO): 213% (open $0.78, close $2.44)
- Digirad Corp. (NSDQ:DRAD): 206% (open $0.62, close $1.90)
- American Shared Hospital Services (AMEX:AMS): 195% (open $1.00, close $2.95)
- SeraCare Life Sciences (NSDQ:SRLS): 187% (open $1.26, close $3.62)
Sources: Google Finance and Yahoo! Finance.
- Biopure Corp. (NSDQ:BPUR): -93% (open $0.15, close $0.01)
- Enteromedics Inc. (NSDQ:ETRM): -72% (open $1.60, close $0.45)
- Cardica Inc. (NSDQ:CRDC): -67% (open $3.50, close $1.15)
- Hansen Medical Inc. (NSDQ:HNSN): -64% (open $8.24, close $2.95)
- Argonaut Technologies Inc. (OTC:AGNT): -50% (open $0.02, close $0.01)
- Intraop Medical Corp. (OTC:IOPD): -38% (open $1.45, close $0.90)
- Synovis Life Technologies Inc. (NSDQ:SYNO): -31% (open $18.28, close $12.57)
- Cambridge Heart Inc. (OTC:CAMH): -30% (open $0.10, close $0.07)
- Biomerica Inc. (OTC:BMRA): -29% (open $0.52, close $0.37)
- Rochester Medical Corp. (NSDQ:ROCM): -27% (open $15.15, close $11.05)
And the 10 biggest losers:
Sources: Google Finance and Yahoo! Finance.
Disclaimer: MassDevice.com’s rankings do not reflect an opinion of companies’ health, prospects or viability. They are intended to provide a snapshot of publicly traded medical device companies and in no way constitute a recommendation to buy or sell any particular security, portfolio of securities, transaction or investment strategy.